Spanish pharmaceutical company Almirall, and Meda, based in Sweden, have entered into an agreement regarding Meda's inhalation products division the business sector that develops the Novolizer, a multidose dry-powder inhaler for administration of products to treat respiratory conditions.
Through the agreement, Meda will market the Novolizer products currently on the market, while Almirall will take over continued R&D for pharmaceutical substances, including Almirall´s pipeline products, with the Novolizer system.
For several years, an agreement has existed with Almirall for the development
of one of its leading respiratory pipeline products, LAS34273 a long-acting
anticholinergic compound for the treatment of chronic obstructive pulmonary
disorder in the Novolizer. The partnership has been strengthened through
Almirall's acquisition of Meda's development unit and intellectual property
rights to the Novolizer technology, the companies said.